This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTHI Transition Therapeutics (TTHI) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Transition Therapeutics Stock (NASDAQ:TTHI) 30 days 90 days 365 days Advanced Chart Get TTHI alerts:Sign Up Key Stats Today's Range$1.52▼$1.5250-Day Range N/A52-Week Range$0.66▼$2.75VolumeN/AAverage Volume70,238 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah. Read More Receive TTHI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Transition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TTHI Stock News HeadlinesHold Rating for Century Therapeutics Amidst Strategic Expansion and Transitional PhaseNovember 7, 2024 | markets.businessinsider.comTG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b Study - Quick FactsSeptember 18, 2024 | markets.businessinsider.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.August 4 at 2:00 AM | Crypto 101 Media (Ad)Ackman exits Lowe's after bet earned $1.3 billion for Pershing Square fundsFebruary 7, 2024 | ca.finance.yahoo.comRelief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D GrowthDecember 5, 2023 | markets.businessinsider.comSchool hid teen's gender transition from parents, leading to runaway, abuse nightmare: lawsuitSeptember 17, 2023 | foxnews.comTG Therapeutics Announces Data from the ULTIMATE IMay 31, 2023 | tmcnet.comTransition Therapeutics to Pay Eli Lilly $1MJanuary 21, 2023 | thestreet.comSee More Headlines TTHI Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Transition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Transition Therapeutics investors own include American Superconductor (AMSC), Atlantic Power (AT), Alphatec (ATEC), Biogen (biib), Foresight Energy (FELP), (FMSA) (FMSA) and Gran Tierra Energy (GTE). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:TTHI CIK1399250 Webwww.transitiontherapeutics.com Phone+1-416-2607770FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TTHI) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transition Therapeutics, Inc. - Please log in to your account or sign up in order to add this asset to your watchlist. Share Transition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.